Xan­thi­nol Nicoti­nate CAS 437-74-1

• Iden­ti­fi­ca­tion
• Prop­er­ties
• Safe­ty Data
• Spec­i­fi­ca­tions & Oth­er Information
• Links
• Quick Inquiry

Iden­ti­fi­ca­tion

CAS Number

437-74-1

Name

Xan­thi­nol Nicotinate

Syn­onyms

1492
207-115-7 [EINECS]
3-Pyridinecar­boxylic acid com­pd with 3,7-dihydro-7-[2-hydroxy-3-[(2-hydroxyethyl)methylamino]propyl]-1,3-dimethyl-1H-purine-2,6-dione (1:1)
3-Pyridinecar­boxylic acid, com­pd. with 3,7-dihydro-7-(2-hydroxy-3-((2-hydroxyethyl)methylamino)propyl)-1,3-dimethyl-1H-purine-2,6-dione (1:1)
3-Pyridinecar­boxylic acid, com­pd. with 3,7-dihydro-7-[2-hydroxy-3-[(2-hydroxyethyl)methylamino]propyl]-1,3-dimethyl-1H-purine-2,6-dione (1:1) [ACD/​Index Name]
437-74-1 [RN]
7-[2-Hydroxy-3-[(2-hydroxyethyl)methylamino]propyl]theophylline com­pd with nico­tinic acid
7-[3-[N-(2-Hydroxyethyl)amino]-2-hydroxypropyl]theophylline nicoti­nate
8G60H12X2D
Acide nico­tinique – 7-{2-hydroxy-3-[(2-hydroxyéthyl)(méthyl)amino]propyl}-1,3-diméthyl-3,7-dihydro-1H-purine-2,6-dione (1:1) [French] [ACD/IUPAC Name]
Com­plamin [Trade name]
Nicoti­nate de xan­ti­nol [French] [INN]
Nicoti­na­to de xan­ti­nol [Span­ish] [INN]
Nico­tinic acid – 7-{2-hydroxy-3-[(2-hydroxyethyl)(methyl)amino]propyl}-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione (1:1) [ACD/IUPAC Name]
Nicotin­säure –7-{2-hydroxy-3-[(2-hydroxyethyl)(methyl)amino]propyl}-1,3-dimethyl-3,7-dihydro-1H-purin-2,6-dion (1:1) [Ger­man] [ACD/IUPAC Name]
pyri­­dine-3-car­boxylic acid – 7-{2-hydroxy-3-[(2-hydroxyethyl)(methyl)amino]propyl}-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione (1:1)
SK 331-A
UNII :8G60H12X2D
Xan­thi­nol Nia­ci­nate [USAN]
Xan­thi­nol nicoti­nate
Xan­ti­nol Nia­ci­nate
Xan­ti­nol nicoti­nate [INN] [Wiki]
Xan­ti­nol Nicoti­nate, (R)-
Xan­ti­nol Nicoti­nate, (S)-
Xan­ti­no­li nicoti­nas [Latin]
Xavin [Trade name]
ксантинола никотинат [Russ­ian]
نيكوتينات كسانتينول [Ara­bic]
尼可占替诺 [Chi­nese]
[437-74-1]
{7-[2-Hydroxy-3-[(2-hydroxyethyl)methylamino]propyl]theophylline,} com­pound with nico­tinic acid (1:1)
108643-57-8 [RN]
3-Pyridinecar­boxylic acid & {3,7-dihydro-7-[2-hydroxy-3-[(2-hydroxyethyl)methylamino]propyl]-1,} 3-dimethyl-1H-purine-2,6-dione (1:1)
3-Pyridinecar­boxylic acid com­pd. with 3,7-dihydro-7-(2-hydroxy-3-((2-hydroxyethyl)methylamino)propyl)-1,3-dimethyl-1H-purine-2,6-dione (1:1)
3-Pyridinecar­boxylic acid com­pd. with 3,7-dihydro-7-[2-hydroxy-3-[ (2-hydroxyethyl)methylamino]propyl]-1, 3-dimethyl-1H-purine-2,6-dione (1:1)
3-Pyridinecar­boxylic acid com­pd. with 3,7-dihydro-7-[2-hydroxy-3-[(2-hydroxyethyl)methylamino]propyl]-1,3-dimethyl-1H-purine-2,6-dione (1:1)
3-Pyridinecar­boxylic acid, com­pd. with 3, {7-dihydro-7-[2-hydroxy-3-[(2-hydroxyethyl)methylamino]propyl]-1,} 3-dimethyl-1H-purine-2,6-dione (1:1)
3-Pyridinecar­boxylic acid, com­pd. with 3, 7-dihydro-7-[2-hydroxy-3-[ (2-hydroxyethyl)methylamino]propyl]-1, 3-dimethyl-1H-purine-2,6-dione (1:1)
3-pyridinecar­boxylic acid, com­pd. with 3,7-dihydro-7-[2-hydroxy-3-[(2-hydroxyethyl)(methyl)amino]propyl]-1,3-dimethyl-1H-purine-2,6-dione (1:1)
7- 2-Hydroxy-3-((2-hydroxyethyl)methylamino)propyl theo­phylline, com­pound with nico­tinic acid (1:1)
7-(2-Hydroxy-3-((2-hydroxyethyl)(methyl)amino)propyl)-1,3-dimethyl-1H-purine-2,6(3H,7H)-dione nicoti­nate
7-(2-Hydroxy-3-((2-hydroxyethyl)methylamino)propyl)theophylline com­pd. with nico­tinic acid
7-(3-(N-(2-Hydroxyethyl)amino)-2-hydroxypropyl)thiophylline nicoti­nate
7-[2-Hydroxy-3-[ (2-hydroxyethyl)methylamino]propyl]theophylline, com­pound with nico­tinic acid (1:1)
7-[2-hydroxy-3-[2-hydroxyethyl(methyl)amino]propyl]-1,3-dimethylpurine-2,6-dione
7-[2-hydroxy-3-[2-hydroxyethyl(methyl)amino]propyl]-1,3-dimethyl-purine-2,6-dione
7-[2-hydroxy-3-[2-hydroxyethyl(methyl)amino]propyl]-1,3-dimethylpurine-2,6-dione;pyridine-3-carboxylic acid
7-{2-hydroxy-3-[(2-hydroxyethyl)methylamino]propyl}-1,3-dimethyl-1,3,7-trihydr opurine-2,6-dione, pyri­­dine-3-car­boxylic acid
Angioamin
Angiomin
Com­plamex
Com­plamin retard
Con­tamex
Lan­d­ri­na
Methoxylin, com­pd. with nico­tinic acid
MFCD00058342 [MDL num­ber]
MFCD12923948 [MDL num­ber]
min. 98%
Niacin [USAN] [USP] [Wiki]
NIACIN ; XAN­THI­NOL
nico­tinic acid [INN] [ACD/IUPAC Name]
Nico­tinic acid – 7-{2-hydroxy-3-[(2-hydroxyethyl)( methyl)amino]propyl}-1,3-dimethyl-3,7-dihydro-1H-p
Nico­tinic acid – 7-{2-hydroxy-3-[(2-hydroxyethyl)-(methyl)amino]propyl}-1,3-dimethyl-3,7-dihydro-1H-p
Nico­tinic acid com­pound with 7-(2-hydroxy-3-((2-hydroxyethyl)(methyl)amino)propyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione (1:1)
Nico­tinic acid, com­pd. with {7-[2-hydroxy-3-[(2-hydroxyethyl)methylamino]propyl]theophylline} (1:1)
Nico­tinic acid, com­pd. with 3,7-dihydro-7-(2-hydroxy-3-((2-hydroxyethyl) methylamino)propyl)-1,3-dimethyl-1H-purine-2,6-dione
Nico­tinic acid, com­pd. with 7-(2-hydroxy-3-((2-hydroxyethyl)methylamino)propyl)theophylline(1:1) (8CI)
Nico­tinic acid, com­pd. with 7-[2-hydroxy-3-[ (2-hydroxyethyl)methylamino]propyl]theophylline (1:1)
Nico­tinic acid, com­pd. with 7-[2-hydroxy-3-[(2-hydroxyethyl)methylamino]propyl]theophylline (1:1)
NICO­TINIC ACID-7-{2-HYDROXY-3-[(2-HYDROX­YETHYL)(METHYL)AMINO]PROPYL}-1,3-DIMETHYL-3,7-DIHY­DRO-1H-P
Pyri­­dine-3-car­boxylic acid [ACD/IUPAC Name]
QA-7530
Sadamin
Sadamine
SK 331 A
SK 331A
Ste­nal­gil
Teon­i­col
Vedrin
Xani­dil
Xan­thi­nol [Wiki]
Xan­thi­no­li­um nico­tinicum
Xan­ti­no­lo nicoti­na­to [DCIT]

SMILES

Cn1c2c(c(=O)n(c1=O)C)n(cn2)CC(CN(C)CCO)O.c1cc(cnc1)C(=O)O

Std­InChI

InChI=1S/C13H21N5O4.C6H5NO2/c1-15(4-5-19)6-9(20)7-18-8-14-11-10(18)12(21)17(3)13(22)16(11)2;8-6(9)5-2-1-3-7-4-5/h8-9,19-20H,4-7H2,1-3H3;1-4H,(H,8,9)

Std­InChIKey

GEPMAHVD­JH­F­B­JI-UHF­F­­FAOYSA-N

Mol­e­c­u­lar Formula

C₁₉H₂₆N₆O₆

Mol­e­c­u­lar Weight

434.446

MDL Number

MFCD00058342

Prop­er­ties

Appear­ance

White crys­talline powder 

Melt­ing Point

180° – 185° C 

Safe­ty Data

WGK Germany

3

Spec­i­fi­ca­tions and Oth­er Infor­ma­tion of Our Xan­thi­nol Nicoti­nate CAS 437-74-1

Assay

≥98.5 %

Loss on Drying

≤0.5 %

Known Appli­ca­tion

Nico­tinic acid is suit­able for the treat­ment of cere­brovas­cu­lar dis­or­ders (such as cere­bral throm­bo­sis, cere­bral embolism, seque­lae of brain trau­ma, seque­lae of brain surgery, seque­lae of stroke, hypox­ic cere­bral soft­en­ing caused by carotid artery occlu­sion, and elder­ly brain dys­func­tion Etc.), coro­nary heart dis­ease, angi­na, myocar­dial infarc­tion (pre­ven­tion of recur­rence), myocardi­tis, migraine, auric­u­lar ver­ti­go, acral arte­r­i­al spasm, inter­mit­tent clau­di­ca­tion, dia­bet­ic gan­grene, throm­bophlebitis, vari­cose veins Ulcers, pul­monary embolism, hem­or­rhoids, frost­bite and hyperlipidemia.

Links

Quick Inquiry